NASDAQ:CASI - CASI Pharmaceuticals Stock Price, Forecast & News

CASI Pharmaceuticals' stock was trading at $1.63 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CASI stock has increased by 27.0% and is now trading at $2.07. View which stocks have been mosted impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CASI Pharmaceuticals.

CASI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for CASI Pharmaceuticals.

CASI Pharmaceuticals Inc (NASDAQ:CASI) announced its quarterly earnings results on Monday, March, 16th. The biotechnology company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.01. The biotechnology company earned $1.34 million during the quarter, compared to analysts' expectations of $1.16 million. View CASI Pharmaceuticals' earnings history.

1 analysts have issued twelve-month price objectives for CASI Pharmaceuticals' stock. Their forecasts range from $3.50 to $3.50. On average, they anticipate CASI Pharmaceuticals' share price to reach $3.50 in the next twelve months. This suggests a possible upside of 69.1% from the stock's current price. View analysts' price targets for CASI Pharmaceuticals.

Media stories about CASI stock have been trending very positive on Monday, according to InfoTrie. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. CASI Pharmaceuticals earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutCASI Pharmaceuticals.

Some companies that are related to CASI Pharmaceuticals include Oyster Point Pharma (OYST), Sangamo Therapeutics (SGMO), Orchard Therapeutics (ORTX), Novavax (NVAX), Krystal Biotech (KRYS), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Translate Bio (TBIO), Aerie Pharmaceuticals (AERI), AVITA MED LTD/S (RCEL), GENFIT S A/ADR (GNFT), Avrobio (AVRO), Passage Bio (PASG), BAVARIAN NORDIC/S (BVNRY) and Atara Biotherapeutics (ATRA).

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include Caladrius Biosciences (CLBS), Frontier Communications (FTR), Energy Transfer LP Unit (ET), Celsion (CLSN), Catalyst Pharmaceuticals (CPRX), InterDigital Wireless (IDCC), Bank of Hawaii (BOH), Novavax (NVAX), Progenics Pharmaceuticals (PGNX) and Rigel Pharmaceuticals (RIGL).

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

CASI Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include IDG Accel China Growth Fund III Associates L.P. (8.28%), Wellington Shields & Co. LLC (1.33%), State Street Corp (0.99%), Charles Schwab Investment Management Inc. (0.31%), California Public Employees Retirement System (0.13%) and Vident Investment Advisory LLC (0.07%). Company insiders that own CASI Pharmaceuticals stock include Brian D Coleman and Wei-Wu He. View institutional ownership trends for CASI Pharmaceuticals.

CASI stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, and Bank of America Corp DE. View insider buying and selling activity for CASI Pharmaceuticals.

CASI stock was acquired by a variety of institutional investors in the last quarter, including IDG Accel China Growth Fund III Associates L.P., Wellington Shields & Co. LLC, State Street Corp, Zebra Capital Management LLC, Charles Schwab Investment Management Inc., Barclays PLC, UBS Group AG, and Vident Investment Advisory LLC. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include Brian D Coleman, and Wei-Wu He. View insider buying and selling activity for CASI Pharmaceuticals.

Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CASI stock can currently be purchased for approximately $2.07.

CASI Pharmaceuticals has a market capitalization of $204.97 million and generates $4.13 million in revenue each year. The biotechnology company earns $-46,030,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. CASI Pharmaceuticals employs 124 workers across the globe. View additional information about CASI Pharmaceuticals.

The official website for CASI Pharmaceuticals is http://www.casipharmaceuticals.com/.

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]